SCHEMBL23891920

SCHEMBL23891920

CCCCC(N)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.47
PDE2A O00408 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
CA2 P00918 1/20 0.39
GRM8 O00222 1/20 0.38
GRM4 Q14833 1/20 0.38
TLR8 Q9NR97 1/20 0.38
EPHX1 P07099 1/20 0.37
TACR1 P25103 1/20 0.37
CYP1A2 P05177 3/20 0.36
CYP3A4 P08684 3/20 0.36
CYP2C9 P11712 3/20 0.36
TSHR P16473 3/20 0.36
CYP2C19 P33261 3/20 0.36
SLC7A5 Q01650 3/20 0.36
TAAR1 Q96RJ0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1729340 1.00 SLC2A1 (0.47) SLC2A1PDE2ASMN1; SMN2MEN1LMNA
SCHEMBL1727664 1.00 SLC2A1 (0.47) SLC2A1PDE2ASMN1; SMN2MEN1LMNA
SCHEMBL3602797 0.89 PDE2A (0.43) SLC2A1PDE2AGRM8GRM4TACR1
SCHEMBL3595268 0.89 PDE2A (0.43) SLC2A1PDE2AGRM8GRM4TACR1
SCHEMBL906156 0.89 PDE2A (0.43) SLC2A1PDE2AGRM8GRM4TACR1
SCHEMBL9350707 0.84 SLC2A1 (0.59) SLC2A1CA2CYP1A2CYP2C19
SCHEMBL9950997 0.84 KIF11 (0.46) PDE2A
SCHEMBL27407732 0.84 SLC2A1 (0.49) SLC2A1LMNACA2TSHR
SCHEMBL1727790 0.82 TACR1 (0.43) SLC2A1CA2EPHX1TACR1CYP3A4
SCHEMBL1727512 0.82 TACR1 (0.43) SLC2A1CA2EPHX1TACR1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3177611-B1 OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES NUEVOLUTION AS (DK) 2021-10-06 EP disclosed